Strengths
We provide a long-term follow-up of the only RCT to date that evaluated the clinical utility of SCS screening trials. Similar to the TRIAL-STIM RCT, the follow-up assessment was independent from industry funding. Few RCTs of SCS are fully independent of industry and none report results to 36 months. We observed some loss to follow-up; however, this was not substantial, considering that 77% of the participants that completed the primary end point at 6 months completed the follow-up at 36 months.